跳至主要内容
临床试验/IRCT20240215061021N1
IRCT20240215061021N1已完成2 期

Effect of standard treatment of three drugs empagliflozin + linagliptin + metformin (trijardi xr) on BMI, lipid profile, vitamin D in type 2 diabetic patients resistant to two drugs metformin + sitagliptin, referring to the endocrinology clinic

Dezfoul University of Medical Sciences0 个研究点目标入组 28 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
28

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • bmi range between 25 and 45
  • Patients with diabetes resistant to treatment with gliclazide or metformin
  • Age more than 18 years
  • Hba1c should be between 7 and 10.5
  • Fbs less than 250
  • Gfr more than 30
  • No change in treatment =12 weeks before the study
  • be treated with metformin + sitagliptin combination drug

排除标准

  • History of recurrent urinary tract infections
  • History of frequent urination
  • Bmi less than 25
  • ACS, STROKe or TIA in the last three months
  • Bariatric surgery at least two years ago
  • Be susceptible to lactic acidosis or pancreatitis

研究者

发起方
Dezfoul University of Medical Sciences

相似试验